Complicated Skin And Skin Structure Infections Drugs Market Report 2026

Complicated Skin And Skin Structure Infections Drugs Market Overview

• Complicated Skin And Skin Structure Infections Drugs market size has reached to $10.36 billion in 2025 • Expected to grow to $16.61 billion in 2030 at a compound annual growth rate (CAGR) of 10.1% • Growth Driver: Rising Skin Disease Prevalence Fueling Growth In Complicated Skin And Skin Structure Infections Drugs Market • Market Trend: Innovative Pediatric Expansion of Dalbavancin (Xydalba) Strengthens Competitive Edge in Complicated Skin and Skin Structure Infections Drugs Market • Asia-Pacific was the largest region in 2025.

What Is Covered Under Complicated Skin And Skin Structure Infections Drugs Market?

Complicated skin and skin structure infections (cSSSI) drugs are a type of medication treating various skin and soft tissue infections (SSTI) that affect the skin and deeper soft tissues, such as muscles, fascia and subcutaneous tissues, caused by bacterial species. Proper management of these infections is crucial to preventing complications and improving patient outcomes. The main types of active ingredients included in drugs for complicated skin and skin structure infections are delafloxacin, vancomycin, ceftaroline, fosamil, linezolid and others. Delafloxacin refers to a class of fluoroquinolone antibiotics that are used to treat skin and skin structure infections caused by certain bacteria. These can be administered through a variety of routes, including oral, topical and parenteral and are used by several end users, such as hospitals, homecare, specialty clinics and others.

What Is The Complicated Skin And Skin Structure Infections Drugs Market Growth Forecast?

The complicated skin and skin structure infections drugs market size is expected to see rapid growth in the next few years. It will grow to $16.61 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to emergence of multidrug-resistant bacteria, advancements in targeted antibiotic therapies, integration of digital health for infection management, rising demand for outpatient treatment options, expansion of biologics and novel antimicrobial agents. Major trends in the forecast period include rising prevalence of antibiotic-resistant skin infections, development of novel antibiotics for deep tissue infections, adoption of advanced drug delivery systems, increasing hospitalization and outpatient care for csssi, focus on patient-centric therapeutic regimens.

What Is The Driver Of The Complicated Skin And Skin Structure Infections Drugs Market?

The increasing prevalence of skin disease is expected to propel the growth of the complicated skin and skin structure infections drugs market going forward. Skin diseases are medical conditions that affect the skin's appearance, structure and function. These conditions can involve the skin, hair, nails and related tissues. Various antibiotic drugs are used to treat resistant bacteria in cSSSI. Thus, the rise in skin disease cases can lead to new cSSSI drug approvals, raise awareness and promote early diagnosis of complicated skin and skin structure infections. For instance, in February 2023, according to Cancer Research UK, a UK-based cancer research organization, the average number of new melanoma skin cancer cases each year in the UK is expected to increase from approximately 20,800 cases in 2023-2025 to around 26,500 cases in 2038-2040. This represents a projected 9% rise in melanoma incidence rates, reaching 33 cases per 100,000 people annually by 2038-2040. Therefore, the increasing prevalence of skin disease drives the growth of the complicated skin and skin structure infections drugs industry.

Key Players In The Global Complicated Skin And Skin Structure Infections Drugs Market

Major companies operating in the complicated skin and skin structure infections drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline plc, Cipla Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Fresenius Kabi, Macleods Pharmaceuticals, Sun Pharmaceutical Industries Limited, Dr Reddy's Laboratories Ltd, Lupin Pharmaceuticals, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, Wockhardt, Paratek Pharmaceuticals, Basilea Pharmaceutica AG, Melinta Therapeutics Inc., Nabriva Therapeutics AG, MerLion Pharmaceuticals GmbH

Global Complicated Skin And Skin Structure Infections Drugs Market Trends and Insights

Major companies operating in the complicated skin and skin structure infections drugs market are developing innovative products, such as dalbavancin, to gain a competitive edge in the market. Dalbavancin is a second-generation semi-synthetic lipoglycopeptide antibiotic that disrupts bacterial cell wall synthesis, effectively killing gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), making it useful in treating acute bacterial skin and skin structure infections (ABSSSI). For instance, in January 2023, AbbVie Inc., a US-based pharmaceutical company, announced the expansion of Xydalba (dalbavancin for injection) approval for pediatric patients across Europe. Xydalba is an intravenous therapy indicated for acute bacterial skin and skin structure infections in adults and children from three months of age. Features include a long half-life allowing infrequent dosing, potent activity against resistant gram-positive pathogens, and a favorable safety profile, aiding clinicians in managing complicated infections efficiently.

What Are Latest Mergers And Acquisitions In The Complicated Skin And Skin Structure Infections Drugs Market?

In September 2023, Novo Holdings, a Denmark-based investment firm, acquired Paratek Pharmaceuticals Inc. for an amount of $462 million. With this acquisition, Novo Holdings sought to advance its antimicrobial-resistance (AMR) strategy and secure in-market assets addressing acute bacterial skin and skin structure infections (ABSSSI), thereby strengthening its position in the high-priority anti-infective drugs space. Paratek Pharmaceuticals is a US-based pharmaceutical company that specializes in manufacturing drugs (NUZYRA, omadacycline) that is approved for treating acute bacterial skin and skin structure infections (ABSSSI) in adults.

What Defines the Complicated Skin And Skin Structure Infections Drugs Market?

The complicated skin and skin structure infections drugs market consists of sales of pain medications, immunosuppressive medications, antiseptics and wound dressings. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Complicated Skin And Skin Structure Infections Drugs Market Report 2026?

The complicated skin and skin structure infections drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the complicated skin and skin structure infections drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.